Welcome to our dedicated page for WORK Medical Technology Group SEC filings (Ticker: WOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The WORK Medical Technology Group LTD (WOK) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer in the medical devices sector. WORK Medical files annual reports on Form 20-F and current reports on Form 6-K, detailing its operations in developing and manufacturing Class I and II medical devices and selling Class I and II disposable medical devices through subsidiaries in China.
In these filings, investors can review information on WORK Medical’s product portfolio of medical consumables and equipment, its sales footprint across 34 provincial-level administrative regions in China, and the registration of 17 products with the U.S. Food and Drug Administration. Form 6-K reports provide updates on interim financial statements and management’s discussion and analysis, extraordinary general meetings and voting results, changes in independent auditors, and capital markets transactions such as registered direct offerings, at-the-market sales agreements, and pre-funded warrants.
Filings also describe share structure changes and Nasdaq listing matters, including approved share consolidations (reverse stock splits), increases in authorized share capital, and correspondence with Nasdaq regarding minimum bid price compliance and potential delisting determinations. These documents outline the reasons for share consolidations, effective dates, and post-consolidation share counts, giving context to changes in the company’s capital structure.
On Stock Titan, users can access WORK Medical’s Forms 6-K and 20-F as they are furnished to the SEC’s EDGAR system, along with AI-powered summaries that highlight key points such as financing terms, governance changes, and listing status updates. The filings page is also a reference point for tracking any future registration statements, prospectus supplements, and other transactional documents that the company incorporates by reference into its shelf registration statements.
WORK Medical Technology Group LTD director Johnson Robert Brian filed an initial Form 3 as a reporting person of the company. This filing establishes his status as a director under insider reporting rules but shows no reportable share holdings or transactions at this time.
HRT Financial LP, a ten percent owner of WORK Medical Technology Group, reported mixed trades in the company’s common stock. On May 28, 2026, it made an open‑market purchase of 1,535,850 shares at $0.09 per share.
On May 29, 2026, HRT Financial then executed an open‑market sale of 2,619,607 shares at $0.10 per share, leaving reported direct holdings at 0 shares. Across both days, this represents a net sale of 1,083,757 shares of WORK Medical common stock.
HRT FINANCIAL LP, a ten percent owner of WORK Medical Technology Group LTD, filed an initial ownership report showing a direct holding of 225,234 shares of Common Stock. This Form 3 records existing ownership and does not report any specific share purchases or sales.
WORK Medical Technology Group LTD disclosed that Wu Zhenguo, a company director, has filed an initial Form 3 insider ownership statement. The structured data shows no reported stock purchases, sales, option exercises, or other transactions in this filing, indicating it is a baseline disclosure of his status as a director.
WORK Medical Technology Group LTD director and COO Yu Baiming filed an initial ownership report showing indirect holdings of Class B Ordinary Shares. The filing reports beneficial ownership of 100,625 Class B Ordinary Shares held indirectly through LWY GROUP LTD, with no buy or sell transactions reported.
WORK Medical Technology Group LTD director and CEO Wu Shuang Jarod has filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing does not list any stock transactions or holdings details and simply establishes him as a reporting insider for WOK.
WORK Medical Technology Group LTD submitted an initial insider ownership report for director Lin Qisheng on Form 3. The data provided shows no reportable transactions, no listed holdings, and no derivative positions for this reporting person at the time of the filing.
WORK Medical Technology Group LTD reported that Liang Ningfang, the company’s Chief Financial Officer, has filed an initial statement of beneficial ownership on Form 3. This filing establishes Liang’s status as an insider of WORK Medical but does not report any share transactions or holdings details in the provided data.
WORK Medical Technology Group Ltd has created a wholly-owned New Zealand subsidiary, WORK MEDICAL TECHNOLOGY LIMITED, which will act as its operations and management headquarters and help expand business in New Zealand and Australia. The company now lists its principal executive offices at 1/88 Cook Street in Auckland, New Zealand, and the prior executive office in China is no longer treated as a principal executive office.
This update is furnished on a Form 6-K and is incorporated by reference into the company’s existing Form F-3 registration statement, becoming part of that shelf registration from the date of filing.
WORK Medical Technology Group LTD reports a change in its board of directors. On March 23, 2026, independent director Xiaoyang Li resigned from the Board, the Audit, Compensation, and Nominating and Corporate Governance Committees, and as chairperson of the Compensation Committee, citing personal reasons.
To fill this vacancy, the Board appointed Dr. Qisheng Lin as an independent director, a member of all three committees, and chairperson of the Compensation Committee, effective the same day. Dr. Lin is a nephrology specialist and academic with roles at Renji Hospital and prior research experience at the Icahn School of Medicine at Mount Sinai. The Board determined he meets the Nasdaq “independent director” standard. This report is incorporated by reference into the Company’s Form F-3 registration statement (File No. 333-289943).